Letter to the Editor on: A. Siegmann et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival. Results of a retrospective study. In: Strahlenther Onkol 2011;187:467-72 (No. 8) (DOI 10.1007/s00066-011-2229-3). P. Ghadjar, D. Zwahlen, D.M. Aebersold: Selection bias is not a good reason for dose intensification in patients with PSA recurrence after radical prostatectomy.
Pirus
P
Ghadjar
D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000532:radiotherapy* / Q000601:surgery*
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen